Skip to content
Preprint · OA via OpenAlex

MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE

Lennart Langenhoff, Jonas Simon, Sandrina Weber, Diana Hubert, Martin Schuler, Marvin Mann, Vuk Puzovic, Grischa Gerwert, Adrian Höveler, Léon Beyer, Lars Tönges, Carsten Kötting, Jörn Güldenhaupt, Brit Mollenhauer, Klaus Bernhard Gerwert

medRxiv · 2025 · ▲ 3 citations

Abstract

Abstract Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA) are characterized by pathological aggregation of misfolded alpha-synuclein (αSyn) in the central and peripheral nervous systems. Seed amplification assays (SAAs) can detect misfolded αSyn in cerebrospinal fluid (CSF), allowing a more precise biological classification of these diseases. Translating biomarker-based diagnostics to blood represents a crucial milestone to democratize access to molecular testing, as blood sampling is minimally invasive and widely scalable. However, current blood-based SAA approaches require extensive sample preprocessing, which introduces variability and has yielded inconsistent results. Here, we present the immuno-infrared-sensor (iRS) platform, which detects misfolded αSyn directly in blood serum without sample preprocessing and without amplification. The iRS measures the secondary-structure distribution of αSyn by distinguishing α-helical/random-coil monomers from β-sheet-rich oligomers and fibrils. This conformational distribution reflects disease-associated structural changes in blood and provides information beyond the binary readout of SAAs. In a combined cohort (n = 127) consisting of 74 individuals with synucleinopathies (PD, DLB, MSA and isolated rapid eye movement sleep behavior disorder (iRBD)) and 53 controls, the assay achieved a receiver operating characteristic area under the curve (ROC AUC) of 0.94 (95% confidence interval (CI), 0.88–0.99), with 88% sensitivity and 89% specificity in serum using a dual-threshold classification that categorized individuals as controls (no misfolding, green), at risk (low misfolding, yellow) or diseased (high misfolding, red). By extending the iRS platform from CSF to blood serum, this study demonstrates αSyn misfolding as a promising blood-based structural biomarker for synucleinopathies. The iRS assay provides a broadly applicable platform technology for more precise biological classification, disease monitoring and assessment of drug response for PD in peripheral blood.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.64898/2025.12.19.25342662
Canonical
link ↗
Fetched
2026-11-15 MST

Cite this

APA
Langenhoff, L., Simon, J., Weber, S., Hubert, D., Schuler, M., Mann, M., Puzovic, V., Gerwert, G., Höveler, A., Beyer, L., Tönges, L., Kötting, C., Güldenhaupt, J., Mollenhauer, B., &amp; Gerwert, K.B. (2025). MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE. <em>medRxiv</em>. https://doi.org/10.64898/2025.12.19.25342662
Vancouver
Langenhoff L, Simon J, Weber S, Hubert D, Schuler M, Mann M, et al. MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE. medRxiv. 2025. doi:10.64898/2025.12.19.25342662.
BibTeX
@unpublished{lennart2025MISFOL, title = {MISFOLDING OF ALPHA-SYNUCLEIN AS BLOOD-BASED BIOMARKER FOR PARKINSON’S DISEASE}, author = {Lennart Langenhoff and Jonas Simon and Sandrina Weber and Diana Hubert and Martin Schuler and Marvin Mann and Vuk Puzovic and Grischa Gerwert and Adrian Höveler and Léon Beyer and Lars Tönges and Carsten Kötting and Jörn Güldenhaupt and Brit Mollenhauer and Klaus Bernhard Gerwert}, journal = {medRxiv}, year = {2025}, doi = {10.64898/2025.12.19.25342662}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings